ziprasidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2865 146939-27-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ziprasidone
  • zaprasidone
  • ziprasidone hydrochloride
  • ziprasidone mesylate
  • geodon
  • ziprasidone HCl
  • ziprasidone mesilate
a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone
  • Molecular weight: 412.94
  • Formula: C21H21ClN4OS
  • CLOGP: 4.86
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 48.47
  • ALOGS: -4.76
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.36 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 5, 2001 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 1007.55 18.62 298 15873 11628 50577325
Blood prolactin abnormal 894.76 18.62 193 15978 1982 50586971
Sexual dysfunction 878.18 18.62 205 15966 3087 50585866
Anosognosia 756.51 18.62 169 16002 2065 50586888
Sedation 715.38 18.62 293 15878 30317 50558636
Tardive dyskinesia 707.79 18.62 203 15968 7076 50581877
Disturbance in social behaviour 697.34 18.62 166 16005 2728 50586225
Dyskinesia 648.59 18.62 266 15905 27595 50561358
Metabolic disorder 621.16 18.62 171 16000 5115 50583838
Personality change 569.22 18.62 162 16009 5483 50583470
Suicide attempt 469.26 18.62 258 15913 51474 50537479
Extrapyramidal disorder 381.61 18.62 143 16028 11627 50577326
Completed suicide 333.01 18.62 300 15871 131589 50457364
Neuroleptic malignant syndrome 320.39 18.62 124 16047 11006 50577947
Akathisia 292.51 18.62 107 16064 8122 50580831
Blood glucose increased 249.46 18.62 196 15975 71128 50517825
Orthostatic hypertension 203.93 18.62 42 16129 336 50588617
Electrocardiogram QT prolonged 197.50 18.62 150 16021 51736 50537217
Parkinsonism 197.15 18.62 82 16089 8765 50580188
Metabolic syndrome 169.39 18.62 46 16125 1301 50587652
Insurance issue 160.90 18.62 51 16120 2497 50586456
Diabetes mellitus 142.35 18.62 121 16050 48912 50540041
Suicidal ideation 131.56 18.62 122 16049 55263 50533690
Psychotic disorder 127.28 18.62 82 16089 21730 50567223
Oculogyric crisis 121.52 18.62 36 16135 1401 50587552
Agitation 118.00 18.62 113 16058 53271 50535682
Tremor 108.29 18.62 157 16014 114746 50474207
Blood prolactin increased 101.63 18.62 38 16133 3061 50585892
Mania 100.26 18.62 55 16116 10861 50578092
Galactorrhoea 94.86 18.62 38 16133 3685 50585268
Hallucination, auditory 87.50 18.62 50 16121 10678 50578275
Obesity 83.19 18.62 57 16114 16718 50572235
Arthralgia 77.88 18.62 22 16149 438680 50150273
Cardio-respiratory arrest 74.56 18.62 89 16082 53803 50535150
Weight increased 72.75 18.62 183 15988 201708 50387245
Respiratory arrest 71.00 18.62 66 16105 29943 50559010
Impulse-control disorder 70.97 18.62 20 16151 650 50588303
Hyperprolactinaemia 70.96 18.62 30 16141 3335 50585618
Paranoia 70.66 18.62 43 16128 10305 50578648
Torsade de pointes 70.27 18.62 45 16126 11790 50577163
Posture abnormal 66.26 18.62 25 16146 2064 50586889
Anxiety 66.07 18.62 163 16008 177443 50411510
Pain 63.80 18.62 55 16116 578848 50010105
Somnolence 58.43 18.62 143 16028 154842 50434111
Type 2 diabetes mellitus 58.11 18.62 63 16108 34312 50554641
Delusion 57.39 18.62 38 16133 10531 50578422
Rapid eye movement sleep behaviour disorder 56.83 18.62 13 16158 177 50588776
Diarrhoea 55.55 18.62 64 16107 588412 50000541
Depression 54.44 18.62 145 16026 165278 50423675
Peripheral swelling 53.67 18.62 3 16168 205933 50383020
Catatonia 52.25 18.62 25 16146 3711 50585242
Pneumonia 50.78 18.62 29 16142 378372 50210581
Joint swelling 50.05 18.62 9 16162 245277 50343676
Dyslipidaemia 49.07 18.62 28 16143 5960 50582993
Adverse drug reaction 48.40 18.62 73 16098 55149 50533804
Rheumatoid arthritis 47.03 18.62 5 16166 202545 50386408
Abnormal behaviour 46.04 18.62 43 16128 19615 50569338
Condition aggravated 45.07 18.62 201 15970 296857 50292096
Substance abuse 44.10 18.62 23 16148 4101 50584852
Muscle rigidity 43.14 18.62 31 16140 9798 50579155
Cardiac arrest 42.51 18.62 87 16084 83564 50505389
Psychomotor hyperactivity 42.35 18.62 30 16141 9271 50579682
Insomnia 41.95 18.62 137 16034 174728 50414225
Overdose 40.76 18.62 95 16076 99632 50489321
Blood triglycerides increased 39.26 18.62 31 16140 11281 50577672
Arthropathy 39.06 18.62 3 16168 157903 50431050
Mental disorder 36.62 18.62 40 16131 21951 50567002
Product use issue 36.52 18.62 3 16168 149472 50439481
Reduced facial expression 36.26 18.62 15 16156 1579 50587374
Swollen tongue 35.88 18.62 45 16126 28585 50560368
Restlessness 35.49 18.62 42 16129 25131 50563822
Cardiac hypertrophy 31.96 18.62 12 16159 977 50587976
Rabbit syndrome 31.40 18.62 9 16162 311 50588642
Systemic lupus erythematosus 31.31 18.62 4 16167 140618 50448335
Aggression 31.05 18.62 36 16135 21080 50567873
Personality change due to a general medical condition 30.69 18.62 7 16164 94 50588859
Treatment failure 30.44 18.62 4 16167 137633 50451320
Toxicity to various agents 30.09 18.62 141 16030 212358 50376595
Alopecia 29.77 18.62 21 16150 245026 50343927
Product substitution issue 29.60 18.62 29 16142 14028 50574925
Intentional overdose 29.40 18.62 63 16108 62441 50526512
Off label use 29.30 18.62 68 16103 474358 50114595
Tachyphrenia 29.28 18.62 12 16159 1233 50587720
Abdominal discomfort 29.28 18.62 19 16152 231622 50357331
Mental status changes 29.04 18.62 46 16125 36226 50552727
Swelling 28.95 18.62 14 16157 200858 50388095
Seizure 28.82 18.62 93 16078 117781 50471172
Torticollis 28.56 18.62 13 16158 1723 50587230
Nasopharyngitis 28.49 18.62 13 16158 192914 50396039
Maternal exposure during pregnancy 28.29 18.62 8 16163 159770 50429183
Fatigue 27.95 18.62 124 16047 707477 49881476
Sinusitis 27.61 18.62 10 16161 170548 50418405
Infection 26.57 18.62 11 16160 172943 50416010
Echolalia 26.56 18.62 7 16164 176 50588777
Cough 26.37 18.62 23 16148 241241 50347712
Trismus 25.68 18.62 15 16156 3333 50585620
Drooling 25.54 18.62 15 16156 3369 50585584
Pyrexia 25.52 18.62 52 16119 380151 50208802
General physical health deterioration 25.46 18.62 7 16164 142427 50446526
Pain in extremity 25.29 18.62 30 16141 272835 50316118
Abdominal pain 25.24 18.62 23 16148 236205 50352748
Drug withdrawal syndrome 24.63 18.62 35 16136 25046 50563907
Bruxism 24.33 18.62 14 16157 3026 50585927
Back pain 24.01 18.62 21 16150 220009 50368944
Rhabdomyolysis 23.98 18.62 44 16127 38983 50549970
Thrombocytopenia 23.33 18.62 6 16165 127667 50461286
Haemoglobin decreased 23.21 18.62 6 16165 127210 50461743
Schizophrenia 22.97 18.62 19 16152 7378 50581575
Amenorrhoea 22.69 18.62 20 16151 8464 50580489
Drug ineffective 22.69 18.62 377 15794 818956 49769997
Irritability 22.68 18.62 36 16135 28390 50560563
Exposure via ingestion 22.68 18.62 13 16158 2790 50586163
Withdrawal syndrome 22.60 18.62 28 16143 17562 50571391
Cogwheel rigidity 22.17 18.62 11 16160 1766 50587187
Suicidal behaviour 22.09 18.62 12 16159 2322 50586631
Organ failure 22.02 18.62 12 16159 2336 50586617
Stereotypy 21.47 18.62 7 16164 375 50588578
Nausea 21.46 18.62 135 16036 705263 49883690
Wound 21.30 18.62 4 16167 105790 50483163
Headache 21.03 18.62 87 16084 506448 50082505
Diabetic coma 20.85 18.62 8 16163 691 50588262
Coprolalia 20.72 18.62 4 16167 22 50588931
Thinking abnormal 20.63 18.62 20 16151 9547 50579406
Apathy 20.60 18.62 18 16153 7530 50581423
Muscle twitching 20.53 18.62 25 16146 15406 50573547
Decreased eye contact 20.19 18.62 6 16165 236 50588717
Granulocytopenia 19.59 18.62 15 16156 5216 50583737
Sepsis 19.55 18.62 9 16162 132916 50456037
Obsessive thoughts 19.50 18.62 7 16164 502 50588451
Muscle tightness 19.42 18.62 20 16151 10260 50578693
Anaemia 19.16 18.62 32 16139 252424 50336529
Pituitary hyperplasia 19.07 18.62 3 16168 3 50588950
Pressure of speech 18.92 18.62 7 16164 547 50588406
Injection site pain 18.84 18.62 6 16165 111018 50477935
Pruritus 18.82 18.62 39 16132 283529 50305424
Coma 18.80 18.62 50 16121 56829 50532124
Female sexual dysfunction 18.71 18.62 4 16167 39 50588914

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 433.27 21.42 159 11841 9590 29552937
Neuroleptic malignant syndrome 308.31 21.42 144 11856 16004 29546523
Akathisia 281.17 21.42 105 11895 6637 29555890
Dyskinesia 278.63 21.42 144 11856 19917 29542610
Tardive dyskinesia 268.13 21.42 95 11905 5163 29557364
Anosognosia 241.95 21.42 58 11942 760 29561767
Blood prolactin abnormal 239.06 21.42 58 11942 802 29561725
Sedation 224.69 21.42 119 11881 17286 29545241
Antipsychotic drug level below therapeutic 221.74 21.42 65 11935 1909 29560618
Therapeutic product effect variable 216.10 21.42 63 11937 1814 29560713
Euphoric mood 211.62 21.42 78 11922 4747 29557780
Disturbance in social behaviour 208.71 21.42 60 11940 1642 29560885
Obsessive-compulsive disorder 204.48 21.42 75 11925 4501 29558026
Disinhibition 203.91 21.42 65 11935 2542 29559985
Suicide attempt 196.15 21.42 139 11861 33971 29528556
Weight increased 191.48 21.42 193 11807 76474 29486053
Extrapyramidal disorder 189.48 21.42 91 11909 10740 29551787
Sexual dysfunction 166.48 21.42 69 11931 5745 29556782
Increased appetite 163.67 21.42 69 11931 5995 29556532
Metabolic disorder 155.65 21.42 58 11942 3637 29558890
Priapism 127.59 21.42 53 11947 4435 29558092
Obesity 125.97 21.42 67 11933 9796 29552731
Aggression 120.22 21.42 106 11894 35435 29527092
Personality change 115.97 21.42 50 11950 4588 29557939
Electrocardiogram QT prolonged 114.74 21.42 104 11896 36033 29526494
Completed suicide 114.69 21.42 161 11839 90085 29472442
Psychotic disorder 105.61 21.42 78 11922 20276 29542251
Agitation 102.74 21.42 115 11885 51189 29511338
Suicidal ideation 100.69 21.42 95 11905 34621 29527906
Bruxism 97.60 21.42 33 11967 1554 29560973
Oppositional defiant disorder 94.09 21.42 25 11975 506 29562021
Decreased eye contact 91.51 21.42 24 11976 461 29562066
Homicidal ideation 89.68 21.42 35 11965 2489 29560038
Catatonia 88.74 21.42 41 11959 4427 29558100
Dyslipidaemia 79.71 21.42 42 11958 6019 29556508
Irritability 76.72 21.42 67 11933 22085 29540442
Oculogyric crisis 74.73 21.42 26 11974 1335 29561192
Trismus 70.75 21.42 29 11971 2344 29560183
Delusion 65.04 21.42 46 11954 11170 29551357
Blood prolactin increased 64.30 21.42 24 11976 1510 29561017
Hallucination, auditory 64.25 21.42 43 11957 9550 29552977
Swollen tongue 63.58 21.42 47 11953 12219 29550308
Mania 63.29 21.42 41 11959 8622 29553905
Serotonin syndrome 62.72 21.42 54 11946 17458 29545069
Drug ineffective 60.90 21.42 299 11701 362871 29199656
Anxiety 59.12 21.42 116 11884 85249 29477278
Psychomotor hyperactivity 57.87 21.42 38 11962 8175 29554352
Leukaemia 57.60 21.42 29 11971 3781 29558746
Crying 56.30 21.42 32 11968 5319 29557208
Paranoia 56.09 21.42 40 11960 9837 29552690
Diarrhoea 55.94 21.42 33 11967 332665 29229862
Choreoathetosis 54.13 21.42 19 11981 1001 29561526
Pneumonia 53.48 21.42 32 11968 320140 29242387
Therapeutic product effect incomplete 52.61 21.42 72 11928 39233 29523294
Leukopenia 50.92 21.42 85 11915 55118 29507409
Speech disorder 49.22 21.42 54 11946 23462 29539065
Schizoaffective disorder 49.14 21.42 18 11982 1074 29561453
Prescribed overdose 48.92 21.42 35 11965 8648 29553879
Coordination abnormal 47.90 21.42 32 11968 7082 29555445
Blood glucose increased 46.82 21.42 85 11915 58899 29503628
Anaemia 46.75 21.42 12 11988 200939 29361588
Dacryostenosis congenital 45.70 21.42 9 11991 42 29562485
Parkinsonism 44.87 21.42 31 11969 7247 29555280
Toxicity to various agents 43.68 21.42 162 11838 173499 29389028
Tic 43.31 21.42 19 11981 1816 29560711
Type 2 diabetes mellitus 42.88 21.42 39 11961 13542 29548985
Abnormal behaviour 41.44 21.42 49 11951 23078 29539449
Muscle rigidity 37.77 21.42 31 11969 9380 29553147
Somnolence 37.67 21.42 103 11897 93852 29468675
Diabetes mellitus 37.61 21.42 62 11938 39769 29522758
Blood creatine phosphokinase increased 36.68 21.42 62 11938 40582 29521945
Tremor 36.08 21.42 87 11913 73451 29489076
Schizophrenia 35.92 21.42 26 11974 6539 29555988
Granulocytopenia 35.71 21.42 25 11975 5969 29556558
Mood altered 35.26 21.42 28 11972 8083 29554444
Affect lability 34.86 21.42 20 11980 3382 29559145
Anger 33.84 21.42 31 11969 10859 29551668
Insomnia 33.31 21.42 95 11905 88666 29473861
Rhabdomyolysis 33.16 21.42 75 11925 60733 29501794
Hypotonia neonatal 33.09 21.42 14 11986 1225 29561302
Torticollis 31.34 21.42 13 11987 1082 29561445
Hyperkinesia 29.66 21.42 14 11986 1585 29560942
Blood triglycerides increased 29.54 21.42 31 11969 12803 29549724
Blunted affect 29.51 21.42 9 11991 303 29562224
Grandiosity 29.23 21.42 9 11991 313 29562214
Pruritus 29.08 21.42 6 11994 116843 29445684
Pyrexia 29.04 21.42 45 11955 287577 29274950
Feminisation acquired 28.28 21.42 6 11994 43 29562484
Acute kidney injury 27.25 21.42 41 11959 265226 29297301
Cough 26.81 21.42 9 11991 126718 29435809
Myopathy toxic 26.52 21.42 9 11991 428 29562099
Opisthotonus 26.19 21.42 9 11991 445 29562082
Asthenia 25.42 21.42 30 11970 215220 29347307
Bipolar disorder 25.06 21.42 16 11984 3279 29559248
Depressed mood 24.86 21.42 32 11968 16416 29546111
Thinking abnormal 24.76 21.42 19 11981 5217 29557310
Thrombocytopenia 24.58 21.42 12 11988 134811 29427716
Condition aggravated 23.27 21.42 119 11881 146176 29416351
Hyperprolactinaemia 23.19 21.42 11 11989 1259 29561268
Arthralgia 23.16 21.42 14 11986 139603 29422924
Neonatal respiratory depression 23.12 21.42 8 11992 404 29562123
Disease progression 23.06 21.42 3 11997 81913 29480614
Insurance issue 23.00 21.42 10 11990 935 29561592
Streptococcal infection 22.81 21.42 17 11983 4471 29558056
Off label use 22.61 21.42 56 11944 300744 29261783
Nervousness 21.99 21.42 25 11975 11281 29551246
Death 21.78 21.42 69 11931 342015 29220512
Sleep disorder 21.73 21.42 37 11963 24349 29538178
Posture abnormal 21.44 21.42 12 11988 1935 29560592

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 1107.57 18.18 359 20820 18506 64459047
Blood prolactin abnormal 1053.44 18.18 231 20948 2501 64475052
Sexual dysfunction 945.52 18.18 250 20929 6221 64471332
Anosognosia 921.25 18.18 208 20971 2597 64474956
Disturbance in social behaviour 838.46 18.18 205 20974 3682 64473871
Sedation 786.40 18.18 345 20834 41117 64436436
Dyskinesia 770.59 18.18 335 20844 39053 64438500
Metabolic disorder 717.30 18.18 209 20970 7488 64470065
Personality change 664.49 18.18 202 20977 8391 64469162
Neuroleptic malignant syndrome 509.46 18.18 219 20960 24777 64452776
Suicide attempt 499.24 18.18 303 20876 70704 64406849
Tardive dyskinesia 499.09 18.18 165 21014 9013 64468540
Completed suicide 489.56 18.18 476 20703 223938 64253615
Extrapyramidal disorder 361.50 18.18 160 21019 19392 64458161
Akathisia 302.52 18.18 121 21058 11389 64466164
Blood glucose increased 283.39 18.18 244 20935 97829 64379724
Electrocardiogram QT prolonged 234.18 18.18 200 20979 79248 64398305
Parkinsonism 219.50 18.18 103 21076 14270 64463283
Psychotic disorder 184.10 18.18 124 21055 34454 64443099
Suicidal ideation 180.86 18.18 160 21019 66382 64411171
Orthostatic hypertension 180.82 18.18 42 21137 597 64476956
Obesity 171.11 18.18 98 21081 20464 64457089
Insurance issue 170.51 18.18 55 21124 2771 64474782
Oculogyric crisis 163.84 18.18 52 21127 2486 64475067
Metabolic syndrome 159.43 18.18 50 21129 2298 64475255
Agitation 147.76 18.18 163 21016 88204 64389349
Aggression 143.54 18.18 120 21059 46112 64431441
Diabetes mellitus 125.87 18.18 131 21048 66343 64411210
Catatonia 120.63 18.18 56 21123 7564 64469989
Decreased eye contact 113.75 18.18 30 21149 735 64476818
Hallucination, auditory 112.94 18.18 70 21109 16869 64460684
Blood prolactin increased 110.00 18.18 42 21137 3486 64474067
Weight increased 108.16 18.18 225 20954 213123 64264430
Oppositional defiant disorder 106.60 18.18 26 21153 460 64477093
Type 2 diabetes mellitus 102.88 18.18 87 21092 33933 64443620
Respiratory arrest 99.53 18.18 104 21075 52881 64424672
Adverse drug reaction 95.89 18.18 95 21084 45369 64432184
Delusion 94.40 18.18 64 21115 17950 64459603
Dyslipidaemia 90.39 18.18 49 21130 9193 64468360
Psychomotor hyperactivity 89.51 18.18 57 21122 14394 64463159
Anxiety 89.28 18.18 202 20977 202447 64275106
Bruxism 87.96 18.18 36 21143 3588 64473965
Diarrhoea 85.00 18.18 68 21111 722636 63754917
Mania 83.29 18.18 57 21122 16229 64461324
Galactorrhoea 81.64 18.18 33 21146 3186 64474367
Homicidal ideation 81.26 18.18 33 21146 3224 64474329
Irritability 79.74 18.18 78 21101 36668 64440885
Pneumonia 78.76 18.18 43 21136 559533 63918020
Drug ineffective 77.44 18.18 505 20674 839742 63637811
Paranoia 76.07 18.18 54 21125 16298 64461255
Priapism 74.96 18.18 33 21146 3937 64473616
Condition aggravated 74.83 18.18 280 20899 372146 64105407
Cardiac arrest 70.53 18.18 156 21023 153908 64323645
Cardio-respiratory arrest 68.64 18.18 119 21060 98274 64379279
Trismus 68.32 18.18 33 21146 4868 64472685
Hyperprolactinaemia 67.86 18.18 31 21148 4034 64473519
Arthralgia 65.13 18.18 32 21147 442228 64035325
Posture abnormal 63.30 18.18 28 21151 3378 64474175
Tremor 63.28 18.18 146 21033 148084 64329469
Granulocytopenia 61.74 18.18 40 21139 10400 64467153
Muscle rigidity 59.74 18.18 48 21131 17425 64460128
Serotonin syndrome 59.68 18.18 69 21110 39213 64438340
Antipsychotic drug level below therapeutic 58.72 18.18 19 21160 966 64476587
Depression 57.85 18.18 161 21018 183130 64294423
Insomnia 56.84 18.18 168 21011 197668 64279885
Rhabdomyolysis 55.13 18.18 104 21075 91622 64385931
Impulse-control disorder 53.47 18.18 20 21159 1568 64475985
Pain 53.41 18.18 62 21117 553449 63924104
Torsade de pointes 51.65 18.18 44 21135 17319 64460234
Pyrexia 51.34 18.18 65 21114 558579 63918974
Abnormal behaviour 50.98 18.18 59 21120 33563 64443990
Peripheral swelling 50.67 18.18 5 21174 209148 64268405
Toxicity to various agents 50.19 18.18 244 20935 363269 64114284
Anaemia 49.11 18.18 32 21147 378648 64098905
Rapid eye movement sleep behaviour disorder 48.92 18.18 13 21166 328 64477225
Choreoathetosis 47.90 18.18 18 21161 1429 64476124
Joint swelling 47.63 18.18 7 21172 215375 64262178
Swollen tongue 47.49 18.18 58 21121 34896 64442657
Euphoric mood 45.86 18.18 28 21151 6563 64470990
Coordination abnormal 44.67 18.18 38 21141 14926 64462627
Blood triglycerides increased 44.61 18.18 42 21137 18824 64458729
Overdose 44.38 18.18 134 21045 159432 64318121
Nausea 42.86 18.18 125 21054 785675 63691878
Mental disorder 42.79 18.18 48 21131 26397 64451156
Cough 42.73 18.18 23 21156 302125 64175428
Blood creatine phosphokinase increased 42.36 18.18 72 21107 58486 64419067
Torticollis 40.79 18.18 18 21161 2159 64475394
Disinhibition 40.28 18.18 18 21161 2225 64475328
Exposure via ingestion 39.79 18.18 23 21156 4879 64472674
Abdominal pain 39.67 18.18 27 21152 312348 64165205
Rheumatoid arthritis 39.60 18.18 4 21175 164290 64313263
Speech disorder 38.30 18.18 62 21117 48379 64429174
Grandiosity 38.22 18.18 12 21167 553 64477000
Reduced facial expression 38.08 18.18 17 21162 2096 64475457
Obsessive-compulsive disorder 37.50 18.18 22 21157 4796 64472757
Haemoglobin decreased 37.46 18.18 9 21170 195054 64282499
Increased appetite 37.10 18.18 29 21150 10117 64467436
Crying 36.92 18.18 39 21140 20051 64457502
Mood altered 36.69 18.18 35 21144 15944 64461609
Somnolence 36.61 18.18 148 21031 203497 64274056
Malaise 36.45 18.18 46 21133 396201 64081352
Restlessness 35.74 18.18 54 21125 39731 64437822
Acute kidney injury 35.56 18.18 58 21121 449182 64028371
Therapeutic product effect variable 35.41 18.18 15 21164 1629 64475924
Hyperkinesia 35.05 18.18 17 21162 2529 64475024
Rabbit syndrome 34.83 18.18 10 21169 338 64477215
Tic 34.60 18.18 17 21162 2602 64474951
Nasopharyngitis 34.01 18.18 11 21168 196062 64281491
Pain in extremity 33.66 18.18 30 21149 303055 64174498
Affect lability 33.53 18.18 26 21153 8964 64468589
Thrombocytopenia 33.17 18.18 16 21163 223785 64253768
Dyspnoea 33.15 18.18 123 21056 718551 63759002
Schizophrenia 32.60 18.18 28 21151 11140 64466413
Febrile neutropenia 31.73 18.18 11 21168 187646 64289907
Renal impairment 30.75 18.18 4 21175 135013 64342540
Abdominal discomfort 30.29 18.18 11 21168 182311 64295242
General physical health deterioration 29.71 18.18 15 21164 204410 64273143
Off label use 29.35 18.18 108 21071 632698 63844855
Schizoaffective disorder 29.34 18.18 13 21166 1574 64475979
Arthropathy 29.00 18.18 3 21176 120964 64356589
Pruritus 28.99 18.18 36 21143 312364 64165189
Substance abuse 28.56 18.18 24 21155 9268 64468285
Thinking abnormal 27.84 18.18 26 21153 11530 64466023
Gastrointestinal haemorrhage 27.67 18.18 5 21174 132307 64345246
Personality change due to a general medical condition 27.56 18.18 7 21172 147 64477406
Headache 27.51 18.18 86 21093 529381 63948172
Tachyphrenia 27.26 18.18 13 21166 1863 64475690
Sepsis 26.54 18.18 22 21157 230319 64247234
Disease progression 26.30 18.18 7 21172 141673 64335880
Infection 26.22 18.18 14 21165 184866 64292687
Fatigue 26.17 18.18 142 21037 748588 63728965
Stereotypy 26.16 18.18 10 21169 832 64476721
Asthenia 25.56 18.18 65 21114 427979 64049574
Erythema 25.33 18.18 15 21164 187055 64290498
Feminisation acquired 25.11 18.18 5 21174 32 64477521
Mental status changes 24.70 18.18 59 21120 61103 64416450
Anger 24.49 18.18 28 21151 15713 64461840
Swelling 24.44 18.18 11 21168 160207 64317346
Alopecia 24.31 18.18 12 21167 165678 64311875
Depressed mood 24.00 18.18 46 21133 40966 64436587
Injection site pain 23.75 18.18 4 21175 111404 64366149
Sleep disorder 23.47 18.18 57 21122 59652 64417901
Drooling 23.44 18.18 17 21162 5302 64472251
Stomatitis 23.23 18.18 4 21175 109601 64367952
Cognitive disorder 23.18 18.18 54 21125 55033 64422520
Ventricular arrhythmia 22.48 18.18 19 21160 7396 64470157
Myopathy toxic 22.43 18.18 9 21170 852 64476701
Sinusitis 22.28 18.18 10 21169 145918 64331635
Treatment noncompliance 22.12 18.18 46 21133 43436 64434117
Sperm concentration decreased 21.94 18.18 5 21174 65 64477488
Corneal reflex decreased 21.90 18.18 7 21172 342 64477211
Echolalia 21.56 18.18 7 21172 360 64477193
Treatment failure 21.25 18.18 6 21173 116810 64360743
Pressure of speech 21.12 18.18 9 21170 992 64476561
Posturing 21.02 18.18 9 21170 1003 64476550
Obsessive thoughts 20.98 18.18 9 21170 1008 64476545
Muscle contractions involuntary 20.69 18.18 13 21166 3204 64474349
Streptococcal infection 20.32 18.18 18 21161 7461 64470092
Drug screen positive 20.14 18.18 16 21163 5713 64471840
Poisoning 20.08 18.18 30 21149 21849 64455704
Diabetic coma 20.06 18.18 9 21170 1122 64476431
Interstitial lung disease 19.78 18.18 4 21175 97728 64379825
Back pain 19.11 18.18 33 21146 250138 64227415
Intentional product use issue 19.10 18.18 4 21175 95360 64382193
Female sexual dysfunction 18.89 18.18 4 21175 36 64477517
Cardiac failure 18.80 18.18 10 21169 132363 64345190
Hyperkalaemia 18.76 18.18 5 21174 101124 64376429
Product substitution issue 18.59 18.18 26 21153 17835 64459718
Hallucination 18.24 18.18 59 21120 72729 64404824

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dacryostenosis congenital 38.95 29.56 8 116 8 84546
Opisthotonus 35.39 29.56 8 116 17 84537

Pharmacologic Action:

SourceCodeDescription
ATC N05AE04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Indole derivatives
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35476 neuroleptics
CHEBI has role CHEBI:37956 antihistamines
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48876 muscarinic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Agitation associated with Schizophrenia indication
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Depression Treatment Adjunct off-label use
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Bradycardia contraindication 48867003
Hyperlipidemia contraindication 55822004 DOID:1168
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Metabolic syndrome X contraindication 237602007 DOID:14221
Neutropenic disorder contraindication 303011007 DOID:1227
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Acquired torsion dystonia contraindication 433493000
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.26 acidic
pKa2 7.35 Basic
pKa3 0.27 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 20MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 40MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 60MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 80MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.32 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
D(1A) dopamine receptor GPCR Ki 8.02 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.30 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.92 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter IC50 7 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 7.36 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 7.57 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.89 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.22 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 8.30 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.32 PDSP
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.14 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 6.82 PDSP
Histamine H1 receptor GPCR Ki 7.33 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.46 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 6.55 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 5.52 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.80 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.80 PDSP
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 1D GPCR Ki 8.70 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.11 PDSP
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.40 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 8.05 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.54 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.44 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR EC50 8.47 WOMBAT-PK
Histone H1.0 Nuclear other Ki 7.82 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.59 PDSP
Alpha-1A adrenergic receptor GPCR Ki 9.30 CHEMBL
Histamine H1 receptor GPCR Ki 7.80 CHEMBL
D(2) dopamine receptor GPCR Ki 8.32 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.38 CHEMBL
Histamine H1 receptor GPCR IC50 6.82 CHEMBL
Transporter Transporter Ki 7.32 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.96 CHEMBL

External reference:

IDSource
4021249 VUID
N0000148690 NUI
D02100 KEGG_DRUG
138982-67-9 SECONDARY_CAS_RN
199191-69-0 SECONDARY_CAS_RN
4021249 VANDF
4030214 VANDF
4030215 VANDF
C0380393 UMLSCUI
CHEBI:10119 CHEBI
CHEMBL708 ChEMBL_ID
CHEMBL1375743 ChEMBL_ID
CHEMBL1712 ChEMBL_ID
CHEMBL3989833 ChEMBL_ID
CHEMBL1200997 ChEMBL_ID
DB00246 DRUGBANK_ID
C092292 MESH_SUPPLEMENTAL_RECORD_UI
60854 PUBCHEM_CID
59 IUPHAR_LIGAND_ID
7155 INN_ID
6UKA5VEJ6X UNII
115698 RXNORM
16791 MMSL
187736 MMSL
331404 MMSL
41113 MMSL
d04747 MMSL
009104 NDDF
009105 NDDF
009579 NDDF
129479007 SNOMEDCT_US
373389002 SNOMEDCT_US
409356003 SNOMEDCT_US
409357007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0052 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0052 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0054 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0054 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0056 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0056 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0058 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0058 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0352 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0352 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0354 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0354 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0356 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0356 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0358 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0358 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-1203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 30 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-1203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 30 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3920 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3920 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3960 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3960 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3980 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3980 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3990 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3990 CAPSULE 80 mg ORAL NDA 32 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7703 CAPSULE 80 mg ORAL ANDA 31 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2164 CAPSULE 20 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2166 CAPSULE 40 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2167 CAPSULE 60 mg ORAL ANDA 30 sections